NAD Augmentation in Diabetes Kidney Disease

Summary

A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.

Timeline

Start

2023-04-13

Primary completion

2026-11-30

Completion

2027-03-31

Drugs

Indications